Pioglitazone (agonist of PPARG) stimulates the growth of Adenomatous Polyposis Coli (APC)-mutated HT-29 human colon cancer cells [19], while troglitazone enhances colon cancer in normal C57BL/6 J mice [20]. This evidence concerns the gene APC and malignant colon neoplasm.